Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUSMEM
2023-503776-25-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Aarhus University Hospital. Primary endpoints: Change in protein expression using DSP around TRMs in epidermis and Change in number of TRMs in epidermis and dermis by IHC. Planned start Apr 2023; status: authorised.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-503776-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503776-25-00.